Brief: Inspira Says Co Anticipates FDA Clearance For INSPIRA ART100 In First Half Of 2024
04/03/2024 14:23
March 4 (Reuters) - Inspira Technologies Oxy BHN Ltd
IINN.O :
* INSPIRA™ ANNOUNCES PLANS TO REPORT THE PRIMARY RESULTS FOR
A
CORE BLOOD OXYGENATION TECHNOLOGY WITHIN DAYS
* INSPIRA TECHNOLOGIES OXY BHN LTD: ANTICIPATED FDA
CLEARANCE FOR
INSPIRA ART100 (GEN 1) IN FIRST HALF OF 2024
Source text for Eikon: ID:nPnbHbHtpa
Further company coverage: IINN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Qtrex Quantum
See all newsBrief: Qtrex Announces Receipt Of Nasdaq Notification Regarding Minimum Bid Price Requirement
Brief: Qtrex Quantum Ltd In Discussions With A US Department Of Defense’S Research Laboratory To Establish A Joint Quantum Development Program
Brief: Qtrex Quantum - Offers Up To 6.8 Million Ordinary Shares For Resale By Selling Shareholder - SEC Filing
Brief: Qtrex Expands Into Quantum Processor Interface With Single-Build Cryogenic Chip Carrier
NASDAQ RESUMED AT 11:03 AM